share_log

智翔金泰(688443.SH)：GR1803注射液纳入突破性治疗品种名单

Zhixiang Jintai (688443.SH): GR1803 injection has been included in the list of breakthrough therapeutic varieties.

Gelonghui Finance ·  Aug 12 05:16

On August 12th, Gelonghui reported that Zhixiang Jintai (688443.SH) announced that its product GR1803 injection was included in the list of breakthrough therapeutic varieties by the National Medical Products Administration's Drug Evaluation Center, and it has been completed public display. GR1803 injection is a dual-specific antibody drug independently developed by the company, with BCMA and CD3 as its target, and registered as a Class 1 biological product for therapeutic use. GR1803 injection is a dual-specific antibody molecule based on the common light chain, whose structure is highly similar to that of a normal monoclonal antibody molecule, which not only facilitates the development of its preparation process, but also reduces the possibility of immunogenicity due to structural differences.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment